DRUG

Bright Minds Biosciences Inc

Add to Watchlist

Advanced Chart

44.770

+3.07(7.362%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

44.780

Open

41.110

VWAP

42.24

Vol

33.38K

Mkt Cap

317.18M

Low

41.000

Amount

1.41M

EV/EBITDA(TTM)

Total Shares

4.46M

363.63M

EV/OCF(TTM)

P/S(TTM)

Bright Minds Biosciences Inc. is a biotechnology company, which is engaged in developing treatments for patients with neurological and psychiatric disorders. The Company is focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders. Its Serotonin (5-HT) is a neurotransmitter in the brain and modulates many biological functions. Dysfunction of serotonin receptors, transporters, and associated neurocircuits is fundamental to many diseases including epilepsies and neuro psychiatric. Its pipeline includes BMB-101, BMB-xxx, BMB-201, and BMB-202. The Company has a portfolio of patented, selective serotonin (5-HT2C, 5-HT2A and 5-HT2C/A-receptor subtypes) agonists that were identified by using high-throughput screening methods in combination with advanced molecular modeling techniques to interrogate the interaction between the drug and its targeted receptors to increase downstream signaling.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

-1.258

-12675%

-0.940

+452.94%

Estimates Revision

The market is revising No Change the revenue expectations for Bright Minds Biosciences Inc. (DRUG) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 63.16%.

EPS Estimates for FY2025

Revise Downward

-3.37%

In Past 3 Month

Stock Price

Go Up

+63.16%

In Past 3 Month

4 Analyst Rating

Wall Street analysts forecast DRUG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DRUG is 82.14 USD with a low forecast of 79.65 USD and a high forecast of 84.63 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 44.770

Low

79.65

Averages

82.14

High

84.63

Current: 44.770

Low

79.65

Averages

82.14

High

84.63

Cantor Fitzgerald

Overweight

initiated

2025-07-02

Reason

Cantor Fitzgerald

Price Target

2025-07-02

initiated

Overweight

Reason

Cantor Fitzgerald assumed coverage of Bright Minds with an Overweight rating and no price target. Bright Minds' lead asset, BMB-101, is a highly selective 5-HT2C receptor agonist in developmental and epileptic encephalopathies and absence epilepsy, the analyst tells investors in a research note. BMB-101 may deliver improved efficacy, safety, and durability vs. competitors, the firm says.

TD Cowen

Joseph Thome

Buy

initiated

2025-05-13

Reason

TD Cowen

Joseph Thome

Price Target

2025-05-13

initiated

Buy

Reason

TD Cowen analyst Joseph Thome initiated coverage of Bright Minds with a Buy rating and no price target. The company's lead asset BMB-101 is a biased 5-HT2C agonist that has the potential to be best in class for the treatment of certain refractory seizure disorders, the analyst tells investors in a research note. The firm says its key opinion leaders have highlighted the unmet need by current options in absence epilepsy.

HC Wainwright & Co.

Patrick Trucchio

Strong Buy

Reiterates

$85

2025-02-19

Reason

HC Wainwright & Co.

Patrick Trucchio

Price Target

$85

2025-02-19

Reiterates

Strong Buy

Reason

Piper Sandler

Yasmeen Rahimi

Buy

Initiates

$93

2025-01-23

Reason

Piper Sandler

Yasmeen Rahimi

Price Target

$93

2025-01-23

Initiates

Buy

Reason

Piper Sandler initiated coverage of Bright Minds Biosciences with an Overweight rating and $93 price target. The firm believes the company's lead asset, BMB-101, is a "differentiated" G-protein biased 5-HT2C agonist positioned to drive sustained efficacy in drug-resistant epilepsies with clean safety. Piper sees BMB-101 as a more potent 5-HT2C agonist compared to bexicaserin with no beta-arrestin recruitment.

Cantor Fitzgerald

Charles Duncan

Buy

Initiates

n/a

2025-01-10

Reason

Cantor Fitzgerald

Charles Duncan

Price Target

n/a

2025-01-10

Initiates

Buy

Reason

Cantor Fitzgerald initiated coverage of Bright Minds Biosciences with an Overweight rating and no price target. The company's emerging pipeline is poised to deliver uncommon clinical value targeting high unmet medical needs in rare epilepsies and central nervous system disorders, the analyst tells investors in a research note.

HC Wainwright & Co.

Patrick Trucchio

Strong Buy

Initiates

$85

2025-01-10

Reason

HC Wainwright & Co.

Patrick Trucchio

Price Target

$85

2025-01-10

Initiates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Bright Minds Biosciences Inc (DRUG.O) is -10.27, compared to its 5-year average forward P/E of -2.73. For a more detailed relative valuation and DCF analysis to assess Bright Minds Biosciences Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.73

Current PE

-10.27

Overvalued PE

4.46

Undervalued PE

-9.91

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.99

Current EV/EBITDA

-3.90

Overvalued EV/EBITDA

1.56

Undervalued EV/EBITDA

-3.53

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00